Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis.

IF 2.9 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2024-05-01 Epub Date: 2024-04-01 DOI:10.1080/14737140.2024.2337266

Jingyang Su, Cui Ni, Yuqian Wu, Jialin Zhang, Zelin Cai, Jinhua Lu, Shengyou Lin, Jue Wang

{"title":"Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis.","authors":"Jingyang Su, Cui Ni, Yuqian Wu, Jialin Zhang, Zelin Cai, Jinhua Lu, Shengyou Lin, Jue Wang","doi":"10.1080/14737140.2024.2337266","DOIUrl":null,"url":null,"abstract":"Objectives: To provide a more comprehensive understanding of the efficacy and safety profile of cabozantinib versus placebo in malignant tumors, we conducted a systematic review and meta-analysis. This involved analyzing a collection of published randomized controlled trials to assess the outcomes.Methods: We used RevMan5.3 software to evaluate the outcomes of the collected studies. The primary outcome we focused on was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and disease control rate (DCR).Results: Our findings revealed that compared to placebo, cabozantinib significantly extended the PFS of patients [hazard ratios (HR) 0.37, 95% confidence intervals (CI): 0.32, 0.43, p < 0.00001]. Additionally, cabozantinib improved the OS of patients [HR 0.78, 95%CI: 0.68, 0.91, p = 0.002]. While it is important to note that cabozantinib was associated with a higher likelihood of causing digestive, cutaneous, and cardiovascular related adverse events [relative risk (RR) 4.40, 95% CI: 3.10, 6.25, p < 0.00001].Conclusion: Based on our analysis, cabozantinib significantly prolonged the PFS and OS of patients with malignant tumors (p < 0.01). We recommend the use of cabozantinib in treating advanced malignant tumors. However, it is important to continuously monitor and manage the drug-related adverse events.Registration: PROSPERO (No. CRD42023449261).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2337266","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To provide a more comprehensive understanding of the efficacy and safety profile of cabozantinib versus placebo in malignant tumors, we conducted a systematic review and meta-analysis. This involved analyzing a collection of published randomized controlled trials to assess the outcomes.

Methods: We used RevMan5.3 software to evaluate the outcomes of the collected studies. The primary outcome we focused on was progression-free survival (PFS), and the secondary outcomes included overall survival (OS) and disease control rate (DCR).

Results: Our findings revealed that compared to placebo, cabozantinib significantly extended the PFS of patients [hazard ratios (HR) 0.37, 95% confidence intervals (CI): 0.32, 0.43, p < 0.00001]. Additionally, cabozantinib improved the OS of patients [HR 0.78, 95%CI: 0.68, 0.91, p = 0.002]. While it is important to note that cabozantinib was associated with a higher likelihood of causing digestive, cutaneous, and cardiovascular related adverse events [relative risk (RR) 4.40, 95% CI: 3.10, 6.25, p < 0.00001].

Conclusion: Based on our analysis, cabozantinib significantly prolonged the PFS and OS of patients with malignant tumors (p < 0.01). We recommend the use of cabozantinib in treating advanced malignant tumors. However, it is important to continuously monitor and manage the drug-related adverse events.

Registration: PROSPERO (No. CRD42023449261).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

卡博替尼治疗恶性肿瘤的疗效和安全性比较：系统综述和荟萃分析。

研究目的为了更全面地了解卡博替尼与安慰剂在恶性肿瘤中的疗效和安全性，我们进行了一项系统回顾和荟萃分析。这包括分析一系列已发表的随机对照试验以评估结果：我们使用RevMan5.3软件对收集到的研究结果进行了评估。我们关注的主要结果是无进展生存期（PFS），次要结果包括总生存期（OS）和疾病控制率（DCR）：我们的研究结果显示，与安慰剂相比，卡博替尼能显著延长患者的无进展生存期[危险比（HR）0.37，95% 置信区间（CI）：0.32，0.43，P = 0.002]。但值得注意的是，卡博替尼会导致更高的消化系统、皮肤和心血管相关不良事件[相对风险（RR）4.40，95% CI：3.10，6.25，P 结论：卡博替尼的不良事件发生率较高：根据我们的分析，卡博替尼能显著延长恶性肿瘤患者的 PFS 和 OS（p 注册）：PROSPERO（编号：CRD42023449261）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.